{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05281471",
            "orgStudyIdInfo": {
                "id": "Olvi-Vec-022"
            },
            "secondaryIdInfos": [
                {
                    "id": "GOG-3076",
                    "type": "OTHER",
                    "domain": "GOG Foundation"
                }
            ],
            "organization": {
                "fullName": "Genelux Corporation",
                "class": "INDUSTRY"
            },
            "briefTitle": "Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)",
            "officialTitle": "A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "efficacy-safety-of-olvi-vec-and-platinum-doublet-bevacizumab-compared-to-physician-s-choice-of-chemotherapy-and-bevacizumab-in-platinum-resistant-refractory-ovarian-cancer-prroc-onprime-gog"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-08-31",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-03-07",
            "studyFirstSubmitQcDate": "2022-03-07",
            "studyFirstPostDateStruct": {
                "date": "2022-03-16",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-21",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Genelux Corporation",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "GOG Foundation",
                    "class": "NETWORK"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.",
            "detailedDescription": "Olvi-Vec (olvimulogene nanivacirepvec, aka GL-ONC1, laboratory name: GLV-1h68) is an oncolytic vaccinia virus-based immunotherapy. This study is to test the hypothesis that the combination of Olvi-Vec followed by further chemotherapy is particularly effective against established tumors by virus-mediated immune activation and re-sensitization of tumor cells to chemotherapy. Participant population includes histologically confirmed non-resectable platinum-resistant/refractory ovarian cancer (PRROC). Determination of progression-free survival, safety and overall survival are key objectives. Participants randomized into the Experimental Arm will receive a single-cycle (2 infusions on two consecutive days) of Olvi-Vec through an intraperitoneal catheter. The catheter is then removed, and patients receive systemically administered platinum-doublet chemotherapy and bevacizumab. The control arm receives the Physician's Choice of chemotherapy and bevacizumab at the same dose and schedule. Biological samples will be obtained from some Experimental Arm participants for virus-shedding testing. Assessment of response to treatment in both arms will be by RECIST 1.1 and iRECIST as assessed by Blinded Independent Central Review. Maintenance/continued treatment with non-platinum chemotherapy and bevacizumab is dependent on a participant being clinically stable until confirmed progressive disease by iRECIST or can no longer tolerate therapy.\n\nDr. Robert W. Holloway (AdventHealth Cancer Institute, Orlando, FL) will serve as the National Principal Investigator for this Phase 3 study in PRROC."
        },
        "conditionsModule": {
            "conditions": [
                "Platinum-resistant Ovarian Cancer",
                "Platinum-refractory Ovarian Cancer",
                "Fallopian Tube Cancer",
                "Primary Peritoneal Cancer",
                "High-grade Serous Ovarian Cancer",
                "Endometrioid Ovarian Cancer",
                "Ovarian Clear Cell Carcinoma"
            ],
            "keywords": [
                "olvimulogene nanivacirepvec",
                "GL-ONC1",
                "GLV-1h68",
                "oncolytic virus",
                "virotherapy",
                "viral therapy",
                "immunotherapy",
                "immunochemotherapy",
                "combination therapy",
                "vaccinia virus",
                "ovarian cancer",
                "fallopian tube cancer",
                "primary peritoneal cancer",
                "platinum resistant",
                "platinum refractory",
                "recurrent ovarian cancer",
                "platinum resensitization",
                "chemoresistance",
                "heavily pre-treated",
                "immune activation",
                "reversal of platinum resistance or refractoriness",
                "resensitize"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Randomization (2:1) is either into the Experimental Arm which is Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab or into the Active Comparator Arm which is Physician's Choice of chemotherapy and bevacizumab.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 186,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Olvi-Vec + Platinum-doublet & bevacizumab",
                    "type": "EXPERIMENTAL",
                    "description": "Olvi-Vec: A total of 2 consecutive days of intraperitoneal catheter infusions in Week 0\n\nPlatinum-doublet \\& bevacizumab (or biosimilar) administered beginning in Week 4 (preferred), but no later than Week 5",
                    "interventionNames": [
                        "Biological: olvimulogene nanivacirepvec",
                        "Drug: Platinum chemotherapy: carboplatin (preferred) or cisplatin",
                        "Drug: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin",
                        "Drug: Bevacizumab (or biosimilar)"
                    ]
                },
                {
                    "label": "Physician's Choice of Chemotherapy & bevacizumab",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Physician's Choice of chemotherapy \\& bevacizumab (or biosimilar) administered beginning in Week 0. Physician's Choice of chemotherapy includes either a single agent non-platinum chemotherapy, or as platinum chemotherapy is allowed as an option, a platinum-doublet (i.e., platinum agent combined with a non-platinum agent).",
                    "interventionNames": [
                        "Drug: Platinum chemotherapy: carboplatin (preferred) or cisplatin",
                        "Drug: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin",
                        "Drug: Bevacizumab (or biosimilar)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "olvimulogene nanivacirepvec",
                    "description": "Olvi-Vec is an engineered oncolytic vaccinia virus",
                    "armGroupLabels": [
                        "Olvi-Vec + Platinum-doublet & bevacizumab"
                    ],
                    "otherNames": [
                        "GL-ONC1 and GLV-1h68"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Platinum chemotherapy: carboplatin (preferred) or cisplatin",
                    "description": "Administered according to local practice",
                    "armGroupLabels": [
                        "Olvi-Vec + Platinum-doublet & bevacizumab",
                        "Physician's Choice of Chemotherapy & bevacizumab"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin",
                    "description": "Administered according to local practice",
                    "armGroupLabels": [
                        "Olvi-Vec + Platinum-doublet & bevacizumab",
                        "Physician's Choice of Chemotherapy & bevacizumab"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Bevacizumab (or biosimilar)",
                    "description": "Administered according to local practice",
                    "armGroupLabels": [
                        "Olvi-Vec + Platinum-doublet & bevacizumab",
                        "Physician's Choice of Chemotherapy & bevacizumab"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Progression-free survival (PFS) by RECIST 1.1 in the Intention-to-Treat (ITT) population (all randomized participants regardless of whether they received any dose of treatment)",
                    "description": "To assess progression-free survival from time of randomization until first documented disease progression based on radiological assessment or death from any cause.",
                    "timeFrame": "From date of randomization up to 12 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Incidence of Treatment-emergent Adverse Events in the ITT population",
                    "description": "Determine safety and tolerability of administering multiple doses of Olvi-Vec via intraperitoneal catheter in combination with platinum-doublet and bevacizumab (or biosimilar) as assessed by CTCAE v. 5.0 following initiation of study treatment until end of study participation.",
                    "timeFrame": "From date of first study treatment until death or study completion; assessed up to 36 months"
                },
                {
                    "measure": "Duration of Response (DOR) by RECIST 1.1 in the ITT population",
                    "description": "Time from date of first response until the first date of progressive disease based on radiological assessment.",
                    "timeFrame": "From date of randomization up to 12 months"
                },
                {
                    "measure": "PFS by RECIST 1.1 in the modified ITT (mITT) population (participants who received at least 1 dose of treatment in either Arm)",
                    "description": "Time from randomization to first documented disease progression based on radiological assessment or death from any cause.",
                    "timeFrame": "From date of randomization up to 12 months"
                },
                {
                    "measure": "PFS by iRECIST in the ITT population",
                    "description": "Time from randomization to first documented disease progression with confirmatory imaging scan performed 4-8 weeks after unconfirmed disease progression or death from any cause.",
                    "timeFrame": "From date of randomization up to 12 months"
                },
                {
                    "measure": "Overall Response Rate (ORR) by RECIST 1.1 in the ITT population",
                    "description": "Ratio of the sum of CR \\& PR divided by the number of ITT participants from start of treatment to confirmation of response.",
                    "timeFrame": "From date of randomization up to 12 months"
                },
                {
                    "measure": "Overall Survival in the ITT population",
                    "description": "Time from randomization until date of death from any cause.",
                    "timeFrame": "From date of randomization until death or study completion; assessed up to 36 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed (from prior treatment) non-resectable ovarian, fallopian tube or primary peritoneal cancer.\n* High-grade serous \\[including malignant mixed Mullerian tumor (MMMT) with metastasis that contains high-grade epithelial carcinoma, FIGO grades 2 \\& 3 allowed\\], endometrioid, or clear-cell ovarian cancer.\n* Performance status ECOG of 0 or 1.\n* Life expectancy of at least 6 months.\n* Received a minimum of 3 prior lines (including the 1st line) of systemic therapy with no maximal limit.\n* Time from Last Platinum of less than or equal to 24 months since the last dose of platinum in the most recent platinum-based line of therapy (excluding using platinum as a radiosensitizer) until consent into this trial.\n* Platinum-resistant or -refractory disease based on platinum-free interval (PFI) from the last dose of the most recent. platinum-based line of therapy (must have received a minimum of 2 doses of platinum in that line) to subsequent disease progression based on radiological assessment. Platinum-refractory: PFI of \\< 1 month (including disease progression while on platinum-based therapy). Platinum-resistant: PFI of 1-6 months.\n* Received prior bevacizumab (or biosimilar) treatment.\n* No contraindication to receive carboplatin, cisplatin or bevacizumab (or biosimilar).\n* Have disease progression after last prior line of therapy based on radiological assessment prior to randomization.\n* At least 1 measurable target lesion per RECIST 1.1 based on abdominal/pelvis imaging scan at screening.\n* Evidence by CT and/or PET scans or physical exam of abdominal/pelvis region likely having disease in the peritoneal cavity (i.e., peritoneal carcinomatosis).\n* Adequate renal, hepatic, bone marrow function, adequate coagulation tests, adequate immune function by lymphocyte count.\n\nExclusion Criteria:\n\n* Tumors of mucinous, low-grade serous, squamous cell, small cell neuroendocrine subtypes, MMMT tumors absent an epithelial component on recent biopsy, or non-epithelial ovarian cancers (e.g., germ cell tumors, Sex-cord tumors).\n* Bowel obstruction within last 3 months prior to screening.\n* Active urinary tract infection, pneumonia, other systemic infections.\n* Active gastrointestinal bleeding.\n* Known current central nervous system (CNS) metastasis.\n* Inflammatory diseases of the bowel.\n* History of HIV infection.\n* Active hepatitis B virus or hepatitis C virus within 4 weeks prior to study.\n* History of thromboembolic event within the prior 3 months.\n* Contraindications for intraperitoneal (IP) catheter placement: Bowel obstruction with distended abdomen, rigid abdomen with bulky anterior wall carcinomatosis, abdominal wall hernia mesh that precludes laparoscopic entry to abdomen.\n* Clinically significant cardiac disease at screening (New York Heart Association Class III/IV).\n* Acute cerebrovascular event(s) such as cerebrovascular accident (CVA) or transient ischemic attack (TIA) in previous 6 months.\n* Oxygen saturation \\<90%.\n* Received prior virus-based gene therapy or therapy with cytolytic virus of any type.\n* Receiving concurrent antiviral agent.\n* Prior malignancy of other histology active within previous 3 years except for locally curable cancers apparently cured such as basal/squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of cervix or breast, any other stage I/II local malignancies.\n* Received chemotherapy, radiotherapy, other anti-cancer biologic therapies within 4 weeks prior to planned treatment.\n* Underwent surgery within 4 weeks, or have insufficient recovery from surgical-related trauma or wound healing, prior to first study treatment in either Arm.\n* Receiving immunosuppressive therapy or steroids (except acute concurrent corticosteroid of no more than 20 mg per day for medical management with prednisolone equivalent.\n* Symptomatic malignant ascites or pleural effusions defined as rapidly progressive ascites with abdominal distension and gastrointestinal dysfunction, pleural effusions with respiratory difficulties requiring frequent paracentesis \\> once every 14 days.\n* Known hypersensitivity to gentamicin.",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "overallOfficials": [
                {
                    "name": "Robert W Holloway, MD",
                    "affiliation": "OnPrime Study",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "The University of South Alabama, Mitchell Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Mobile",
                    "state": "Alabama",
                    "zip": "36604",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Stefanie White",
                            "role": "CONTACT",
                            "phone": "251-445-9834",
                            "email": "swhite@southalabama.edu"
                        },
                        {
                            "name": "Jennifer M Scalici, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.69436,
                        "lon": -88.04305
                    }
                },
                {
                    "facility": "University of Arizona Cancer Center",
                    "status": "RECRUITING",
                    "city": "Tucson",
                    "state": "Arizona",
                    "zip": "85719",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Claudia Al Khairi",
                            "role": "CONTACT",
                            "phone": "520-626-0975",
                            "email": "calkhairi@arizona.edu"
                        },
                        {
                            "name": "Setsuko K. Chambers, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.22174,
                        "lon": -110.92648
                    }
                },
                {
                    "facility": "City of Hope",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Edward Wang, MD, PhD",
                            "role": "CONTACT",
                            "phone": "877-467-3411",
                            "email": "edwang@coh.org"
                        },
                        {
                            "name": "Edward Wang, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "UC San Diego Health - Moores Cancer Center",
                    "status": "RECRUITING",
                    "city": "La Jolla",
                    "state": "California",
                    "zip": "92093",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alexandrea Cronin",
                            "role": "CONTACT",
                            "phone": "858-822-3975",
                            "email": "aocronin@health.ucsd.edu"
                        },
                        {
                            "name": "Michael McHale, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Ramez Eskander, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.84727,
                        "lon": -117.2742
                    }
                },
                {
                    "facility": "Hoag Gynecologic Oncology",
                    "status": "RECRUITING",
                    "city": "Newport Beach",
                    "state": "California",
                    "zip": "92663",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Esmeralda Martinez",
                            "role": "CONTACT",
                            "phone": "949-764-5827",
                            "email": "Esmeralda.Martinez@hoag.org"
                        },
                        {
                            "name": "Alberto Mendivil, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.61891,
                        "lon": -117.92895
                    }
                },
                {
                    "facility": "UCI Health Chao Family Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Orange",
                    "state": "California",
                    "zip": "92868",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Krishnansu S. Tewari, MD",
                            "role": "CONTACT",
                            "phone": "714-456-7971",
                            "email": "ktewari@hs.uci.edu"
                        },
                        {
                            "name": "Krishnansu S. Tewari, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.78779,
                        "lon": -117.85311
                    }
                },
                {
                    "facility": "AdventHealth Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32804",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Karla Hernandez-Cruz",
                            "role": "CONTACT",
                            "phone": "407-609-4437",
                            "email": "Karla.Hernandezcruz@AdventHealth.com"
                        },
                        {
                            "name": "Robert W Holloway, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                },
                {
                    "facility": "Tampa General Hospital/University of South Florida",
                    "status": "RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33606",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Monica Rengifo Pardo, MD",
                            "role": "CONTACT",
                            "phone": "813-844-5842",
                            "email": "mrengifopardo@tgh.org"
                        },
                        {
                            "name": "Matthew L. Anderson, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "Women's Cancer Associates with Women's Care Florida",
                    "status": "RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33713",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Megan Indermaur, MD",
                            "role": "CONTACT",
                            "phone": "727-826-0795",
                            "email": "mindermaur@womenscarefl.com"
                        },
                        {
                            "name": "Rebekah Little, CRC",
                            "role": "CONTACT",
                            "phone": "727-826-0795",
                            "phoneExt": "6",
                            "email": "rlittle@womenscarefl.com"
                        },
                        {
                            "name": "Megan Indermaur, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "Indiana University Simon Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Indianapolis",
                    "state": "Indiana",
                    "zip": "46202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Cheri West, RN",
                            "role": "CONTACT",
                            "phone": "317-278-3021",
                            "email": "chawest@iupui.edu"
                        },
                        {
                            "name": "Jessica E. Parker, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.76838,
                        "lon": -86.15804
                    }
                },
                {
                    "facility": "Holy Cross Hospital",
                    "status": "RECRUITING",
                    "city": "Silver Spring",
                    "state": "Maryland",
                    "zip": "20910",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lyudmila Igorevna Kalnitskaya, MBA, MS",
                            "role": "CONTACT",
                            "phone": "301-754-7552",
                            "email": "kalnitsl@holycrosshealth.org"
                        },
                        {
                            "name": "James F Barter, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.99067,
                        "lon": -77.02609
                    }
                },
                {
                    "facility": "Karmanos Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48201",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Robert Morris, MD",
                            "role": "CONTACT",
                            "phone": "313-576-9442",
                            "email": "rmorris@med.wayne.edu"
                        },
                        {
                            "name": "Robert Morris, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "Washington University School of Medicine",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Linda Odibo",
                            "role": "CONTACT",
                            "phone": "314-362-1705",
                            "email": "odibol@wustl.edu"
                        },
                        {
                            "name": "Premal Thaker, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Mercy Hospital St. Louis",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63141",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Crystal Tindall, BSN, RN",
                            "role": "CONTACT",
                            "phone": "314-251-7058",
                            "email": "Crystal.tindall@mercy.net"
                        },
                        {
                            "name": "Jessica Black",
                            "role": "CONTACT",
                            "email": "Jessica.Black@mercy.net"
                        },
                        {
                            "name": "Dan-Arin Silasi, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Center of Hope",
                    "status": "RECRUITING",
                    "city": "Reno",
                    "state": "Nevada",
                    "zip": "89511",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Peter Lim, MD",
                            "role": "CONTACT",
                            "phone": "775-327-4611",
                            "email": "Plim@cohreno.com"
                        },
                        {
                            "name": "Peter Lim, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.52963,
                        "lon": -119.8138
                    }
                },
                {
                    "facility": "Levine Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Charlotte",
                    "state": "North Carolina",
                    "zip": "28204",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Leah Wilson",
                            "role": "CONTACT",
                            "phone": "980-442-4866",
                            "email": "Leah.J.Wilson@atriumhealth.org"
                        },
                        {
                            "name": "Erin K Crane, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.22709,
                        "lon": -80.84313
                    }
                },
                {
                    "facility": "Cleveland Clinic",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jackie Ludwig",
                            "role": "CONTACT",
                            "phone": "440-312-4523",
                            "email": "ludwigj@ccf.org"
                        },
                        {
                            "name": "Peter Rose, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Kettering Health",
                    "status": "RECRUITING",
                    "city": "Kettering",
                    "state": "Ohio",
                    "zip": "45429",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Daniel Geyer",
                            "role": "CONTACT",
                            "phone": "937-395-6017",
                            "email": "daniel.geyer@ketteringhealth.org"
                        },
                        {
                            "name": "Tammy Bonham",
                            "role": "CONTACT",
                            "phone": "937-395-8483",
                            "email": "tammy.schleich@ketteringhealth.org"
                        },
                        {
                            "name": "Thomas J. Reid, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.6895,
                        "lon": -84.16883
                    }
                },
                {
                    "facility": "Oklahoma University Health Stephenson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Oklahoma City",
                    "state": "Oklahoma",
                    "zip": "73104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Debra Richardson, MD",
                            "role": "CONTACT",
                            "phone": "405-271-1112",
                            "phoneExt": "31839",
                            "email": "Debra-Richardson@ouhsc.edu"
                        },
                        {
                            "name": "Ashma Acharya",
                            "role": "CONTACT",
                            "phone": "405-271-8001",
                            "phoneExt": "18001",
                            "email": "Ashma-Acharya@ouhsc.edu"
                        },
                        {
                            "name": "Debra Richardson, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.46756,
                        "lon": -97.51643
                    }
                },
                {
                    "facility": "AHN West Penn Hospital",
                    "status": "RECRUITING",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15224",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sarah Crafton, MD",
                            "role": "CONTACT",
                            "phone": "412-578-1116",
                            "email": "clinicaltrials@ahn.org"
                        },
                        {
                            "name": "Sarah Crafton, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                },
                {
                    "facility": "Hollings Cancer Center",
                    "status": "RECRUITING",
                    "city": "Charleston",
                    "state": "South Carolina",
                    "zip": "29425",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Crystal Knox",
                            "role": "CONTACT",
                            "phone": "843-792-2803",
                            "email": "knoxc@musc.edu"
                        },
                        {
                            "name": "Whitney S Graybill, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.77657,
                        "lon": -79.93092
                    }
                },
                {
                    "facility": "Chattanooga's Program in Women's Oncology",
                    "status": "RECRUITING",
                    "city": "Chattanooga",
                    "state": "Tennessee",
                    "zip": "37403",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Stephen DePasquale, MD",
                            "role": "CONTACT",
                            "phone": "423-266-3633",
                            "email": "sedepasquale@gmail.com"
                        },
                        {
                            "name": "Kim Donelson, LPN CCRP",
                            "role": "CONTACT",
                            "phone": "423-266-3636",
                            "email": "Kimberly.Donelson@erlanger.org"
                        },
                        {
                            "name": "Stephen DePasquale, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.04563,
                        "lon": -85.30968
                    }
                },
                {
                    "facility": "Providence Sacred Heart Medical Center & Children's Hospital",
                    "status": "RECRUITING",
                    "city": "Spokane",
                    "state": "Washington",
                    "zip": "99204",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jodie Mactagone, CRC",
                            "role": "CONTACT",
                            "phone": "509-474-3821",
                            "email": "Jodie.mactagone@providence.org"
                        },
                        {
                            "name": "Melanie Bergman, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.65966,
                        "lon": -117.42908
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "31567308",
                    "type": "BACKGROUND",
                    "citation": "Mori KM, Giuliano PD, Lopez KL, King MM, Bohart R, Goldstein BH. Pronounced clinical response following the oncolytic vaccinia virus GL-ONC1 and chemotherapy in a heavily pretreated ovarian cancer patient. Anticancer Drugs. 2019 Nov;30(10):1064-1066. doi: 10.1097/CAD.0000000000000836."
                },
                {
                    "pmid": "34686353",
                    "type": "RESULT",
                    "citation": "Manyam M, Stephens AJ, Kennard JA, LeBlanc J, Ahmad S, Kendrick JE, Holloway RW. A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer. Gynecol Oncol. 2021 Dec;163(3):481-489. doi: 10.1016/j.ygyno.2021.10.069. Epub 2021 Oct 20. Erratum In: Gynecol Oncol. 2022 May;165(2):401. doi: 10.1016/j.ygyno.2022.02.014."
                },
                {
                    "type": "RESULT",
                    "citation": "Holloway RW, Mendivil AA, Kendrick JE, Abaid LN, Brown JV, Fitzsimmons CK, Kennard JA, King M, LeBlanc J, Lopez K, Manyam M, McKenzie ND, Mori KM, Stephens AJ, Sarfraz A. 2020 International Gynecologic Cancer Society, Oral Plenary Session presentation of VIRO-15 Phase 2 Trial Data, Robert Holloway, AdventHealth Cancer Institute, Orlando, FL. International Journal of Gynecologic Cancer 2020;30:A9-A10"
                },
                {
                    "pmid": "37227734",
                    "type": "RESULT",
                    "citation": "Holloway RW, Mendivil AA, Kendrick JE, Abaid LN, Brown JV, LeBlanc J, McKenzie ND, Mori KM, Ahmad S. Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial. JAMA Oncol. 2023 Jul 1;9(7):903-908. doi: 10.1001/jamaoncol.2023.1007."
                }
            ],
            "seeAlsoLinks": [
                {
                    "label": "Genelux Corporation's Sponsor website",
                    "url": "http://www.genelux.com/"
                },
                {
                    "label": "Genelux Corporation's preclinical publications",
                    "url": "https://www.genelux.com/pre-clinical-publications/"
                },
                {
                    "label": "Genelux Corporation's clinical publications",
                    "url": "http://www.genelux.com/clinical-publications/"
                },
                {
                    "label": "The GOG Foundation's Partner website",
                    "url": "http://www.gog.org"
                },
                {
                    "label": "IGCS 2020 Oral Plenary: Dr. Robert W. Holloway - Oncolytic vaccinia (Olvi-Vec) primed immunochemotherapy in platinum-resistant/refractory ovarian cancer",
                    "url": "https://ijgc.bmj.com/content/30/Suppl_3/A9"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010051",
                    "term": "Ovarian Neoplasms"
                },
                {
                    "id": "D000077216",
                    "term": "Carcinoma, Ovarian Epithelial"
                },
                {
                    "id": "D000005185",
                    "term": "Fallopian Tube Neoplasms"
                },
                {
                    "id": "D000055331",
                    "term": "Adenomyoepithelioma"
                },
                {
                    "id": "D000018262",
                    "term": "Adenocarcinoma, Clear Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004701",
                    "term": "Endocrine Gland Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000010049",
                    "term": "Ovarian Diseases"
                },
                {
                    "id": "D000000291",
                    "term": "Adnexal Diseases"
                },
                {
                    "id": "D000005831",
                    "term": "Genital Diseases, Female"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000005833",
                    "term": "Genital Neoplasms, Female"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000006058",
                    "term": "Gonadal Disorders"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000005184",
                    "term": "Fallopian Tube Diseases"
                },
                {
                    "id": "D000018193",
                    "term": "Neoplasms, Complex and Mixed"
                },
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "relevance": "LOW"
                },
                {
                    "id": "M12974",
                    "name": "Ovarian Neoplasms",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1704",
                    "name": "Carcinoma, Ovarian Epithelial",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17363",
                    "name": "Vaccinia",
                    "relevance": "LOW"
                },
                {
                    "id": "M20408",
                    "name": "Adenocarcinoma, Clear Cell",
                    "asFound": "Clear Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M28121",
                    "name": "Adenomyoepithelioma",
                    "asFound": "Clear Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8328",
                    "name": "Fallopian Tube Neoplasms",
                    "asFound": "Fallopian Tube Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M7863",
                    "name": "Endocrine Gland Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12972",
                    "name": "Ovarian Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M3643",
                    "name": "Adnexal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8943",
                    "name": "Genital Diseases, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8945",
                    "name": "Genital Neoplasms, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9163",
                    "name": "Gonadal Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M8327",
                    "name": "Fallopian Tube Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4352",
                    "name": "Ovarian Cancer",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4354",
                    "name": "Ovarian Epithelial Cancer",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2189",
                    "name": "Fallopian Tube Cancer",
                    "asFound": "Fallopian Tube Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2125",
                    "name": "Epithelial-myoepithelial Carcinoma",
                    "asFound": "Clear Cell Carcinoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000017239",
                    "term": "Paclitaxel"
                },
                {
                    "id": "D000077143",
                    "term": "Docetaxel"
                },
                {
                    "id": "D000068258",
                    "term": "Bevacizumab"
                },
                {
                    "id": "D000016190",
                    "term": "Carboplatin"
                },
                {
                    "id": "D000093542",
                    "term": "Gemcitabine"
                },
                {
                    "id": "D000004317",
                    "term": "Doxorubicin"
                },
                {
                    "id": "C000506643",
                    "term": "Liposomal doxorubicin"
                },
                {
                    "id": "C000080625",
                    "term": "Taxane"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000972",
                    "term": "Antineoplastic Agents, Phytogenic"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000050257",
                    "term": "Tubulin Modulators"
                },
                {
                    "id": "D000050256",
                    "term": "Antimitotic Agents"
                },
                {
                    "id": "D000050258",
                    "term": "Mitosis Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000020533",
                    "term": "Angiogenesis Inhibitors"
                },
                {
                    "id": "D000043924",
                    "term": "Angiogenesis Modulating Agents"
                },
                {
                    "id": "D000006133",
                    "term": "Growth Substances"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000006131",
                    "term": "Growth Inhibitors"
                },
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000000903",
                    "term": "Antibiotics, Antineoplastic"
                },
                {
                    "id": "D000059005",
                    "term": "Topoisomerase II Inhibitors"
                },
                {
                    "id": "D000059003",
                    "term": "Topoisomerase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M18650",
                    "name": "Carboplatin",
                    "asFound": "System",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7492",
                    "name": "Doxorubicin",
                    "asFound": "Entire",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19537",
                    "name": "Paclitaxel",
                    "asFound": "Sessions",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2985",
                    "name": "Gemcitabine",
                    "asFound": "Mg/kg",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M1668",
                    "name": "Docetaxel",
                    "asFound": "Management",
                    "relevance": "HIGH"
                },
                {
                    "id": "M231",
                    "name": "Albumin-Bound Paclitaxel",
                    "relevance": "LOW"
                },
                {
                    "id": "M246",
                    "name": "Bevacizumab",
                    "asFound": "Non-",
                    "relevance": "HIGH"
                },
                {
                    "id": "M227339",
                    "name": "Liposomal doxorubicin",
                    "asFound": "Administered intravenously",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6182",
                    "name": "Cisplatin",
                    "relevance": "LOW"
                },
                {
                    "id": "M147959",
                    "name": "Taxane",
                    "asFound": "Collaboration",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26197",
                    "name": "Tubulin Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M26196",
                    "name": "Antimitotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M22318",
                    "name": "Angiogenesis Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M9231",
                    "name": "Growth Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M4222",
                    "name": "Anti-Bacterial Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4224",
                    "name": "Antibiotics, Antitubercular",
                    "relevance": "LOW"
                },
                {
                    "id": "M29348",
                    "name": "Topoisomerase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}